Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

Authors: Kang D, Passarell JA, Abutarif MA, Mendell J, Yin O
Publication: Blood
Keywords: area under curve, basic local alignment search tool, blast cells, blood platelets, bone marrow, Cmax, colorectal cancer, complete remission, cyp3a protein, cytochrome P450, human
Division: Cognigen

Introduction:

Quizartinib is a once-daily, oral, highly potent and selective FLT3 inhibitor that has shown clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3 internal tandem duplications in the phase 3 QuANTUM-R trial (Cortes et al, Lancet Oncol 2019; NCT02039726). In this analysis, exposure-response relationships of select efficacy endpoints of quizartinib were evaluated

By, Dongwoo Kang, Julie Passarell, Malaz A Abutarif, Jeanne Mendell, Ophelia Yin